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Background/aim: As SARS-CoV-2 continues to spread worldwide, this study brings to light the link that anakinra, a recombinant IL-1
receptor antagonist, has in averting grave clinical outcomes. The objectives of this meta-analysis are to investigate the effects of anakinra
in interventional groups compared to control/standard of care groups on mortality along with the provision of a prevalence estimate of
the variables associated with death (C-reactive protein-CRP, ferritin, acute respiratory distress syndrome-ARDS).
Materials and methods: According to the PRISMA 2020 statement guidelines, a systematic search was conducted from December
19, 2020, until December 10, 2021, with keywords including COVID-19, coronavirus, SARS-CoV-2, anakinra, mortality, across the
following databases: PubMed/MEDLINE, Scopus, Web of Science, CINAHL Plus, and Cochrane. A random-effects model was applied
using RevMan 5.4 for all statistical analyses.
Results: The meta-analysis pooled in 1297 participants with 565 (43.6%) patients in the anakinra group. When comparing to the
control/standard of care group, the anakinra group had a much lower risk of death (RR = 0.47. 95% CI = 0.37–0.59, Z = 6.44; P < 0.001).
In addition to the risk of death being reduced by around 50% in the interventional group, prognostic indicators such as CRP and ferritin
were improved with fewer occurrences of severe ARDS.
Conclusion: Patients with COVID-19 pneumonia may be treated with anakinra as a safe and viable treatment modality to defer adverse
outcomes such as a death in the 28-day period. Despite an auspicious premise, our findings must be used with caution as adequately
powered randomized, placebo-controlled trials are required to corroborate these findings.
Key words: Anakinra, cytokine storm, COVID-19, mortality, meta-analysis

1. Introduction
In December 2019, the severe acute respiratory coronavirus
2 (SARS-CoV-2) was identified in Wuhan, China that led
to a pandemic in early 2020. Coronavirus disease 2019
(COVID-19) continues to spread across the world [1]. With
the recent omicron and delta variant amid other strains
emerging across countries worldwide, the clinical spectrum
of COVID-19 ranges from no clinical symptoms to sepsis,
organ dysfunction, and ultimately death [2]. While the
presence of the many available vaccines has offered certain
protective benefits, effective antiinflammatory treatment
is required as a viable treatment modality to ensure that
mortality rates are decreased [3].
Inflammation plays a pivotal role in the pathophysiology
of COVID-19 [4]. In line with initial reports, critical

COVID-19 patients show higher proinflammatory
cytokines [5]. In patients with severe hyper-inflammation,
the proinflammatory cytokine interleukin-1β plays a
central role in predisposing them to macrophage activation
syndrome [3,5]. The activation of the endothelium may
lead to hypotension, fluid extravasation, and possibly
death [3]. As a recombinant IL-1 receptor antagonist
(IL-1Ra), anakinra is currently a preferred treatment
approach for patients with rheumatoid arthritis, Still’s
disease, and cryopyrin-associated periodic syndrome [5].
With the increasing interest in anakinra as an adjuvant
antiinflammatory treatment modality in COVID-19,
primary clinical studies suggest that there is a decrease
in mortality risk in addition to improved respiratory
outcomes [2].
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The objective of this meta-analysis is to investigate
the effects of anakinra in interventional as compared to
control/standard of care (SoC) groups on mortality, along
with providing a prevalence estimate of the variables
associated with death (CRP, Ferritin, ARDS).
2. Materials and methods
As per the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) 2020 statement
[6], a systematic search was conducted from December
2019 until December 10, 2021, using keywords including
COVID-19, coronavirus, SARS-CoV-2, Anakinra, and
mortality using the BOOLEAN logic (and/or). The
following databases were searched: PubMed/MEDLINE,
Scopus, Web of Science, CINAHL Plus, and Cochrane.
Preprints were omitted due to the unreliability of
methodologies and the quality of the studies. The inclusion
criteria comprised only quantitative primary research
studies, i.e. only cohort studies, interventional studies, and

Figure 1. PRISMA flowchart.
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clinical trials employing an interventional and a control/
SoC group. Case series, case reports, letters, systematic
reviews, and meta-analyses were omitted. During the
systematic search, the data was entered to EndNote
X9, which is a management software tool (Clarivate
Analytics). An umbrella methodology was utilized where
the reference lists of all screened articles were reviewed
to find any studies that met the inclusion criteria. The
PRISMA flowchart is depicted in Figure 1.
All investigators screened the titles and abstracts
before reaching a full-text reviewal phase to determine
the included studies. Any disagreements were resolved
by active discussion among the investigators. An a-priori
methodology was employed using a Delphi process
to prioritize the outcome of interest and to collate the
findings [7].
The quality appraisal for the included studies was
conducted using the Grading of Recommendations,
Assessment, Development, and Evaluation (GRADE)
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criteria. Using the tool, we evaluated the risk of biases
associated with the participant selection, confounding
variables, and the outcome assessment. Of all the ten
studies included in this meta-analysis, there was moderate
bias present due to nonrandomized and cohort study types
included. We additionally checked for publication bias by
generating a funnel plot.
The primary outcome included mortality from any
cause in the 28 days among all studies. Since a study level
outcome data for factors associated with mortality were
unavailable, we provided a brief qualitative overview of the
variables related to mortality and also made implications
for clinical trials.
All investigators assessed the eligibility based on the
inclusion criteria. The data of all studies was extracted
as the author, year, study type, country, sample size,
route of drug administration, and dosage of anakinra
into a shared spreadsheet. For the quantitative analysis,
the dichotomous data for death was enlisted into the
software. This dichotomous data was presented as a risk
ratio employing 95% confidence intervals. The metaanalysis was conducted using Review Manager version 5.4
(Cochrane). The findings were presented along with the I2
index value and the p-value (≤0.05) to test for statistically
significant associations.
When computing the severity of acute respiratory
distress syndrome, the Berlin modification of the American
European Consensus Committee (AECC) definition was
utilized with classifications as follows:
1. Mild-moderate: PaO₂/FiO₂ ≥ 100
2. Severe: PaO₂/FiO₂ ≤100
No funding was obtained for this study. Ethical
approval was not obtained as only secondary clinical data
was utilized for the purposes of this meta-analysis.
3. Results
Of the 437 studies identified across all databases, 136
duplicates were removed. Of these, 301 were screened, and
256 were sought for retrieval. With consensus among all
investigators, only 69 studies were assessed for eligibility,
of which 58 did not meet the inclusion criteria. In total,
9 observational studies and 1 randomized controlled trial
were included in this meta-analysis (Figure 1).
The characteristics of included studies are listed in
Table. Out of all studies, 3 were conducted in France and
Italy respectively, two in Italy, and one each in Netherlands
and Greece. Five studies employed the intravenous route
of drug administration, whereas five utilized a primary
subcutaneous approach (Table).
All ten studies reported data on mortality within the
28-day period and were eligible to be included in this
meta-analysis. As compared to the standard of care group,
the anakinra group had a much lower risk of death (RR

= 0.47. 95% CI = 0.37–0.59, Z = 6.44, P < 0.001). Using
the random-effects model, the I2 value was 20% suggesting
low levels of heterogeneity in the included studies (Figure
2). A sensitivity analysis was conducted by removing
Kyriazopoulou et al., 2021 (weight = 16.2%) and Cavalli
et al., 2020 (weight = 12.8%) from the funnel plot. The
results were recomputed (RR = 0.5, 95% CI = 0.39–0.64,
Z = 5.36, P < 0.001). The sensitivity analysis results led
to similar findings as with the original analysis, where
the anakinra group had a much-reduced risk of death of
50%, as compared to the SoC group, with strong statistical
association (P < 0.001) (Figure 2).
On observing the factors associated with mortality in
the 28 days, it was noted that 22 (11%) patients out of 208
had CRP > 100 mg/dl in the anakinra group. On comparing
the results in the SoC groups, 107 (29%) of 364 patients
had CRP > 100 mg/dL. These results provided insight
into the lessened risk of high CRP in patients treated with
anakinra as compared to standard of care groups. On
noting hyperferritinemia by comparing Ferritin levels, it
was found that 15 (11%) of 137 patients had > 1000 ng/mL
levels in the anakinra group as compared to 31 (31%) of the
101 patients in the SoC group, suggesting that intervention
reduced risks of hyperferritinemia.
The prevalence of severe ARDS (PaO₂/FiO₂ ≤ 100)
in the anakinra group was 18 (17%) of 109 patients as
compared to 49 (44%) of 95 patients in the SoC group. The
results indicated that the SoC group had a higher risk of
severe ARDS as compared to the anakinra group. The risk
of mild to moderate ARDS was also determined (PaO₂/
FiO₂ ≥ 200–300). It was found that the anakinra group
had a 9% risk of mild-moderate ARDS (n = 19/217) as
compared to a 21% risk in the SoC group (n = 72/350).
On visually inspecting the funnel plot, it may be stated
that the demarcations of the 10 included studies tend to fit
the criteria for an inverted funnel shape on the top, with
one deviation (Cauchois et al., 2020) from the symmetrical
shape. Based on these findings, it may be inferred that
there was minimal publication bias present in this metaanalysis (Figure 3).
4. Discussion
This meta-analysis finds that the risk of death decreases
by 47% for patients admitted with COVID-19 induced
pneumonia to hospitals when treated with anakinra as
compared to control/SoC. A randomized controlled trial
addresses the efficacy of anakinra in the patient population
[14]. Studies identify that the therapeutic intervention
for patients with severe COVID-19 pneumonia may
be confined to a therapeutic window before advanced
respiratory failure occurs. The use of anakinra across
several case series, cohorts, and trials has been
encouraging, though not concrete for clinical use. Notably,
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45 vs. 24
59 vs. 55

Oman

Observational

Observational

Observational

Observational

Observational

Randomized
France
controlled trial

Cavalli et al., 2020 [10]

Bozzi et al., 2021[11]

Kooistra et al., 2020 [12]

Balkhair et al., 2021 [13]

CORIMUNO-19, 2021 [14]

65 vs. 55

62 vs. 275

52 vs. 44

Italy

Observational

Observational

Pontali et al., 2021[16]

Franzetti et al., 2021 [17]

56 vs. 56

63 vs. 44

130 vs. 130

*Intravenous approach used if the patient is on invasive mechanical ventilation

Italy

Greece

Kyriazopoulou et al., 2021[15] Observational

Netherlands 21 vs. 39

Italy

Italy

France

12 vs. 10

Huet et al., 2020 [9]

France

Observational

100 mg twice a day for 72 h, then 100 mg daily for 7 days

300 mg/day for 5 day, then tapered with lower dosing over 3 days

Subcutaneous*

Intravenous

Subcutaneous

Intravenous

Subcutaneous

Intravenous

Subcutaneous*

7 d at 100 mg four times a day SC or 200 mg three times daily IV

100 mg every 8 h for 3 days, with tapering

100 mg once daily for 10 days

200 mg twice a day on days 1–3, 100 mg twice on day 4, 100 mg once on day 5

100 mg twice daily for 3 days, followed by 100 mg daily for 7 days

300 mg anakinra intravenously, followed by 100 mg every six h

100 mg twice a day for 72 h, then 100 mg daily for 7 days SC or 5 mg/kg twice a
day intravenously

Intravenous and
Either 5 mg/kg twice a day IV [high dose] or 100 mg twice a day SC [low dose]
subcutaneous

Subcutaneous

Intravenous

Sample size
Route of
(Anakinra vs.
Anakinra dosage
administration
Control/SoC)

Cauchois et al, 2020 [8]

Country

Study type

Author, year

Table. Characteristics of included studies.

MALIK et al. / Turk J Med Sci

MALIK et al. / Turk J Med Sci

Figure 2. Forest plot for mortality as the primary endpoint across all included studies (N = 9).

Figure 3. Funnel plot to visualize publication biases.

the inflammatory biomarker thresholds used to define
hyper inflammation are not uniformly reported across
the observational studies included in this study. It may
be stated that the identification of these biomarkers and
their thresholds in advanced inflammation, or with early
inflammation, may aid in administering a low or high dose
of anakinra. A study conducted among those with Arab
ethnicity found significant differences in mortality on the
use of anakinra (24% in the intervention vs. 67% in the
control group, P = 0.013). The only RCT included in this
meta-analysis was conducted in France, suggesting that
the availability of racial and ethnically stratified data is
scarce when it comes to the assessment of anakinra as a
viable treatment option for COVID-19 [18].
The CORIMUNO trial found that the requirement for
invasive mechanical ventilation was reduced among those
treatments with anakinra (Odds ratio = 0.38, P = 0.02),
and the mortality risk was also reduced in nonintubated

patients (Odds ratio = 0.32, P < 0.001) [18]. The trial’s
objectives were to assess the safety and efficacy of anakinra
in nonhospitalized intubated patients. To understand the
correct timing of anakinra administration and adjuvant
use of invasive mechanical ventilation in hospitalized
intubated patients, further testing ought to be done in
randomized placebo-controlled trials [18]. This will aid
both low- and middle-income countries and high-income
countries in overcoming the limitations of intensive care
unit admissions and the limited oxygenation supplies
by limiting adverse events if commenced with Anakinra
before invasive mechanical ventilation is required.
A cohort study identified that patients treated with a
combination of methylprednisolone and anakinra (13.9%)
had lower mortality rates as compared to controls (35.6%)
(P = 0.004) [11]. It may be stated that a combination
treatment of steroids and anakinra may be a valid
therapeutic option in COVID-19 patients presenting with
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respiratory failure and hyper inflammation and also in
mechanically ventilated patients. Randomized controlled
trials with arms for anti-IL-1 therapy and steroids alone are
required to corroborate these findings.
As identified earlier, some patients with COVID-19
are likely to develop the hyperinflammatory presentation
known as the cytokine storm [3]. This condition is lifethreatening, requiring intensive care unit admission along
with monitoring of inflammatory patterns, ferritin levels,
multi-organ failure, and hemodynamic stability [2]. The
primal trigger for the cytokine storm syndrome may be
IL-1α. These mediators lead to an uncontrolled immune
response, resulting in the production of proinflammatory
interleukins [2,4]. Those who do not present with lifethreatening inflammatory responses may also benefit from
immunomodulating treatment options [18].
Certain limitations must be stated. This meta-analysis
primarily employed observational cohort studies, with
only one RCT, which raises concerns about potential
confounding variables in the interventional and control
groups. In the control group, the number of patients with
high CRP and ferritin and the number of patients with
severe lung involvement was found to be higher than
the anakinra group. This may make anakinra seem like
a better and more viable option than standard therapy.

Various implications for clinical trials must be noted
when conducting such analyses in the wake of the ongoing
COVID-19 pandemic. These include establishing necessary
biomarkers for evaluation pre and postintervention.
Furthermore, the trials’ setting must be broadened in that
groups from all racial and ethnic backgrounds be enrolled.
The primary and secondary outcomes must be stratified
based on the early and late use of anakinra dependent upon
days from onset of symptoms and severity, the dosage and
use of medication, and the invasive ventilation parameters
before anakinra.
In patients with COVID-19, anakinra is a safe and viable
therapeutic adjuvant to defer adverse outcomes such as
death within 28 days. This meta-analysis provides moderatequality evidence that an improvement in inflammatory
markers, i.e. CRP and Ferritin lab components, are present
with intervention, along with less prevalence of ARDS
in the treatment groups. Our findings must be used with
caution as adequately powered randomized, placebocontrolled trials are required to corroborate these findings.
Acknowledgment/Disclaimers/Conflict of interest
No acknowledgments. No funding was obtained for this
paper. There are no conflicts of interest declared by all
authors.

References
1.

Doskaliuk B, Yatsyshyn R, Klishch I, Zimba O. COVID-19
from a rheumatology perspective: bibliometric and altmetric
analysis. Rheumatology International 2021; 41 (12): 20912103. doi: 10.1007/s00296-021-04987-0.

2.

Kyriazopoulou E, Huet T, Cavalli G, Gori A, Kyprianou M, et
al. Effect of anakinra on mortality in patients with COVID-19:
a systematic review and patient-level meta-analysis. Lancet
Rheumatology 2021; 3 (10): 690-697. doi: 10.1016/S26659913(21)00216-2.

3.

4.

5.

6.

552

7.

Sarfraz A, Sarfraz Z, Sanchez-Gonzalez M, Michel J, Michel G,
et al. Randomized controlled trials of remdesivir in hospitalized
coronavirus disease 2019 patients: a meta-analysis. Turkish
Journal of Emergency Medicine 2021; 21 (2): 43-50. doi:
10.4103/2452-2473.309139.

8.

Schulert GS, Grom AA. Pathogenesis of macrophage activation
syndrome and potential for cytokine- directed therapies.
Annual Review of Medicine 2015; 66 :145-59. doi: 10.1146/
annurev-med-061813-012806.

Cauchois R, Koubi M, Delarbre D, Manet C, Carvelli J, et al.
Early IL-1 receptor blockade in severe inflammatory respiratory
failure complicating COVID-19. Proceedings of the National
Academy of Sciences of the United States of America 2020; 117
(32): 18951-18953. doi: 10.1073/pnas.2009017117.

9.

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS,
et al. COVID-19: consider cytokine storm syndromes and
immunosuppression. The Lancet 2020; 395 (10229): 10331034. doi: 10.1016/S0140-6736(20)30628-0.

Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, et
al. Anakinra for severe forms of COVID-19: a cohort study.
Lancet Rheumatology 2020; 2 (7): e393-e400. doi: 10.1016/
S2665-9913(20)30164-8.

10.

Cavalli G, Larcher A, Tomelleri A, Campochiaro C, Della-Torre
E, et al. Interleukin-1 and interleukin-6 inhibition compared
with standard management in patients with COVID-19 and
hyperinflammation: a cohort study. Lancet Rheumatology
2021; 3 (4): 253-261. doi: 10.1016/S2665-9913(21)00012-6.

11.

Bozzi G, Mangioni D, Minoia F, Aliberti S, Grasselli G, et al.
Anakinra combined with methylprednisolone in patients with
severe COVID-19 pneumonia and hyperinflammation: An
observational cohort study. Journal of Allergy and Clinical
Immunology 2021; 147 (2): 561-566.e4. doi: 10.1016/j.
jaci.2020.11.006.

Kooistra EJ, Waalders NJB, Grondman I, Janssen NAF,
de Nooijer AH, et al. Anakinra treatment in critically ill
COVID-19 patients: a prospective cohort study. Critical Care
2020; 24 (1): 688. doi: 10.1186/s13054-020-03364-w.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC,
et al. The PRISMA 2020 statement: An updated guideline for
reporting systematic reviews. PLoS Medicine 2021; 18 (3):
e1003583. doi: 10.1371/journal.pmed.1003583.

MALIK et al. / Turk J Med Sci
12.

Kooistra EJ, Waalders NJB, Grondman I, Janssen NAF,
de Nooijer AH, et al. Anakinra treatment in critically ill
COVID-19 patients: a prospective cohort study. Critical Care
2020; 24 (1): 688. doi: 10.1186/s13054-020-03364-w.

13.

Balkhair A, Al-Zakwani I, Al Busaidi M, Al-Khirbash A, Al
Mubaihsi S, et al. Anakinra in hospitalized patients with severe
COVID-19 pneumonia requiring oxygen therapy: Results of
a prospective, open-label, interventional study. International
Journal of Infectious Diseases 2021; 103: 288-296. doi:
10.1016/j.ijid.2020.11.149.

14.

15.

CORIMUNO-19 Collaborative group. Effect of anakinra versus
usual care in adults in hospital with COVID-19 and mild-tomoderate pneumonia (CORIMUNO-ANA-1): a randomised
controlled trial. The Lancet Respiratory Medicine 2021; 9 (3):
295-304. doi: 10.1016/S2213-2600(20)30556-7.
Kyriazopoulou E, Panagopoulos P, Metallidis S, Dalekos GN,
Poulakou G, et al. An open label trial of anakinra to prevent
respiratory failure in COVID-19. Elife 2021; 10: e66125. doi:
10.7554/eLife.66125.

16.

Pontali E, Volpi S, Signori A, Antonucci G, Castellaneta M,
et al. Efficacy of early anti-inflammatory treatment with high
doses of intravenous anakinra with or without glucocorticoids
in patients with severe COVID-19 pneumonia. The Journal of
Allergy and Clinical Immunology 2021; 147 (4): 1217-1225.
doi: 10.1016/j.jaci.2021.01.024.

17.

Franzetti M, Forastieri A, Borsa N, Pandolfo A, Molteni C,
et al. IL-1 Receptor antagonist anakinra in the treatment of
COVID-19 acute respiratory distress syndrome: a retrospective,
observational study. Journal of Immunology 2021; 206 (7):
1569-1575. doi: 10.4049/jimmunol.2001126.

18.

Sarfraz A, Sarfraz Z, Barrios A, Agadi K, Thevuthasan S, et al.
Understanding and promoting racial diversity in healthcare
settings to address disparities in pandemic crisis management.
Journal of Primary Care and Community Health 2021;12:
21501327211018354. doi: 10.1177/21501327211018354.

553

